Comparison of the prognostic effect of sarcopenia on atezolizumab plus bevacizumab and lenvatinib therapy in hepatocellular carcinoma patients

Comparison of the prognostic effect of sarcopenia on atezolizumab plus bevacizumab and lenvatinib therapy in hepatocellular carcinoma patients

Abstract Background and Aim Sarcopenia has received much attention as a poor prognostic factor in various fields, and has also been reported to worsen prognosis in patients with hepatocellular carcinoma (HCC) treated with sorafenib or lenvatinib (LEN). Atezolizumab/bevacizumab (ATZ/BEV) is recommend...

Full description

Bibliographic Details
Main Authors: Katsuya Toshida, Shinji Itoh, Takahiro Tomiyama, Akinari Morinaga, Yukiko Kosai, Takahiro Tomino, Takeshi Kurihara, Yoshihiro Nagao, Kazutoyo Morita, Noboru Harada, Tomoharu Yoshizumi
Format: Article
Language:English
Published: Wiley 2022-07-01
Series:JGH Open
Subjects:
atezolizumab plus bevacizumab
hepatocellular carcinoma
lenvatinib
sarcopenia
Online Access:https://doi.org/10.1002/jgh3.12777

Internet

https://doi.org/10.1002/jgh3.12777

Similar Items